TB: OVER 85% CURE RATE SEEN IN MODIFIED BPAL REGIMEN TRIAL
30-07-2023
By Admin
CURRENT AFFAIRS FOR 30TH JULY, 2023
TB: OVER 85% CURE RATE SEEN IN MODIFIED BPAL REGIMEN TRIAL
Recently, the BPaL regimen trial was carried out in India for patients with pre-XDR TB or treatment intolerant/ non-responsive MDR pulmonary TB.
• It is an all oral, short-course treatment using just three drugs– bedaquiline, pretomanid, and linezolid.
• Treatment lasts only for 26 weeks
• Although approved by the WHO, it is yet to be implemented in India.
• India's target– reduce TB incidence by 80% and TB deaths by 90% by 2025.